Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCL-KL-004
- Development stage
- Preclinical
- Lead developer
- Bioclonal
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
BCL-KL-004 is a preclinical-stage monoclonal antibody developed by Bioclonal as part of its KL Program. The program focuses on targeting specific peptide-based targets associated with neurodegenerative conditions, specifically Alzheimer's disease. While the exact molecular target within the KL program remains undisclosed by the sponsor, the asset is designed to address neurodegeneration through antibody-mediated intervention. It is one of several candidates (BCL-KL-001 to BCL-KL-004) within this program aimed at modulating pathological peptide interactions in the central nervous system.
- Other names
- BCL-KL-004BCL-KL004BCL-KL 004
02
Targets
KLK4 (Kallikrein-related peptidase 4)
Beyond the preview
Go deeper on BCL-KL-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCL-KL-004.